Hanmi Pharm's Dyslipidemia Combination Drug 'Rosuzet' Enters Mexico Market

Local Brand 'NAXZALLA'... Accelerating Targeting of 15 Trillion Market

[Asia Economy Reporter Jihee Kim] Hanmi Pharmaceutical's combination drug for dyslipidemia, 'Rosuzet,' has entered the Mexican market, which is considered the largest pharmaceutical market in Latin America.

Hanmi Pharmaceutical announced on the 4th that it has launched 'NAXZALLA' in three dosages through its partner MSD. NAXZALLA is the product name for Rosuzet in Mexico.

Previously, Hanmi Pharmaceutical signed export contracts for Rosuzet with MSD in the United States for 23 countries globally.

Rosuzet is a combination drug that contains two active ingredients for treating dyslipidemia: rosuvastatin and ezetimibe. It works by dual inhibition of cholesterol synthesis and absorption in the liver and intestines, effectively lowering blood LDL-C levels. Four papers on Rosuzet have been published in SCI-level international journals. Rosuzet has been growing over 20% annually in the domestic dyslipidemia market.

The Mexican pharmaceutical market is valued at approximately 15 trillion KRW annually, making it the second largest in Latin America after Brazil. It continues to grow at a high rate of over 10% annually. Notably, Mexico ranks second in the world for obesity rate after the United States. Due to this, the incidence of cardiovascular and metabolic diseases such as dyslipidemia is high, leading to rapid expansion of the related pharmaceutical market.

In addition to the countries covered by the export contract with MSD, Hanmi Pharmaceutical is continuing efforts to locally launch Rosuzet in many countries across regions including Argentina, Asia, and Africa.

Woongsoo Woo, CEO of Hanmi Pharmaceutical, said, “Rosuzet is a combination drug developed by a Korean pharmaceutical company that has achieved the number one prescription sales domestically among single specialty drugs. We will do our best to ensure that the success in Korea continues globally, including in Latin America.”

This content was produced with the assistance of AI translation services.